Dec. 12, 2013
/PRNewswire/ -- Byetta lawsuits (
) and other product liability claims involving a class of Type 2 diabetes drugs called incretin mimetics continue to move forward in a multidistrict litigation now underway in U.S. District Court, Southern District of
, Bernstein Liebhard LLP reports. According to an Order dated
, the Court has approved the use of a Master Complaint and Short Form Complaint for all cases filed in the litigation. All of the lawsuits pending in the proceeding involve similar allegations that Byetta, as well as Januvia, Janumet and Victoza, can increase a patient's risk of developing pancreatic cancer. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452)
"Our Firm has heard from numerous individuals concerned about the association between Byetta and pancreatic cancer. The adoption of the Master and Short Form Complaints will do much to streamline the process for filing a Byetta lawsuit," says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Byetta lawsuit reviews to patients who took this medication and were diagnosed with pancreatic cancer, thyroid cancer or pancreatitis.
Byetta Pancreatic Cancer Allegations
Byetta and other incretin mimetics, including Januvia, Janumet and Victoza, mimic the action of incretin hormones in the intestinal track to stimulate the pancreas to produce insulin. The
U.S. Food & Drug Administration (FDA)
announced in March that it was investigating a possible connection between incretin mimetics like Byetta and pancreatic cancer. The review was prompted by the findings from an unpublished study that indicated this class of Type 2 diabetes medications could cause precancerous changes in the cells of the pancreas. The FDA has since noted that it was unable to reach any conclusion regarding this possible risk, but its review is ongoing.
A month after the FDA announced its review, the Institute for Safe Medicine Practices published the results of an analysis that showed the FDA's Adverse Event Reporting Database had received 263 reports of Byetta pancreatitis, 71 cases of Byetta pancreatic cancer, and 14 incidents of Byetta thyroid cancer in a single 12-month period. That study was followed by the June publication of a British Medical Journal investigation that found the manufacturers of Byetta and other incretin mimetics may have downplayed the drugs' potential to harm the pancreas.